The role of Certican (everolimus, rad) in the many pathways of chronic rejection.
Standard
The role of Certican (everolimus, rad) in the many pathways of chronic rejection. / Nashan, Björn.
In: TRANSPL P, Vol. 33, No. 7-8, 7-8, 2001, p. 3215-3220.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
Nashan, B 2001, 'The role of Certican (everolimus, rad) in the many pathways of chronic rejection.', TRANSPL P, vol. 33, no. 7-8, 7-8, pp. 3215-3220. <http://www.ncbi.nlm.nih.gov/pubmed/11750380?dopt=Citation>
APA
Nashan, B. (2001). The role of Certican (everolimus, rad) in the many pathways of chronic rejection. TRANSPL P, 33(7-8), 3215-3220. [7-8]. http://www.ncbi.nlm.nih.gov/pubmed/11750380?dopt=Citation
Vancouver
Nashan B. The role of Certican (everolimus, rad) in the many pathways of chronic rejection. TRANSPL P. 2001;33(7-8):3215-3220. 7-8.
Bibtex
@article{5f4fee92330d4c6fa56542a4f26bc944,
title = "The role of Certican (everolimus, rad) in the many pathways of chronic rejection.",
author = "Bj{\"o}rn Nashan",
year = "2001",
language = "Deutsch",
volume = "33",
pages = "3215--3220",
journal = "TRANSPL P",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "7-8",
}
RIS
TY - JOUR
T1 - The role of Certican (everolimus, rad) in the many pathways of chronic rejection.
AU - Nashan, Björn
PY - 2001
Y1 - 2001
M3 - SCORING: Zeitschriftenaufsatz
VL - 33
SP - 3215
EP - 3220
JO - TRANSPL P
JF - TRANSPL P
SN - 0041-1345
IS - 7-8
M1 - 7-8
ER -
